MAY 15, 2018 6:31 PM PDT

Rett Syndrome: Possible Drug Treatment

WRITTEN BY: Nouran Amin

A research study published in Cell Reports explains that a new drug was seen to reduce symptoms of Rett Syndrome in preclinical models while activating dormant neurons, a characteristic of this genetic disorder. The study was led by Dr. Manel Esteller, the Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL) and Dr. Sonia Guil, an investigator at the same research group.

Rett syndrome is one of the most frequent causes of intellectual disability in women second only to Down Syndrome. The main genetic cause of Rett Syndrome is mutations in the embryo that affect the MECP2 gene, which produces a protein known as a regulator for gene expression. As of now, there is no pharmacotherapies for treating this disease and current research is focused on trying to control its most serious phenotypes, such as epileptic and respiratory cries. The study was led by Dr. Manel Esteller, the Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL) and Dr. Sonia Guil, an investigator at the same research group.

Child w/ Rett Syndrome

"We knew for some years that the brains of Rett syndrome girls were inflamed, so we decided to test whether a drug that inhibits a central neuroinflammatory protein called glycogen synthase kinase-3B (GSK3B) could reverse part of the symptoms. As with any experimental treatment, we started with a preclinical model of the disease, studying it in mice that have the same MECP2 deficiency as in human Rett syndrome" explains Dr. Manel Esteller. "The results have been very promising; agent SB216763 has been able to lengthen the life of the animals, significantly reducing tremors, breathing difficulties and mobility limitations. But what is really remarkable is that the inhibition of GSK3B also causes an "awakening" of the sleeping neurons of the syndrome: these brain cells are now beginning to regain contact between them and communication between neuronal synapses increases," explains IDIBELL researcher, and he concludes: "Our findings provide a new way of improving the quality of life of these patients and now it is the neurologists' job to demonstrate their applicability in patients with Rett Syndrome. In any case, we have to be aware that the mutation in the MECP2 gene is still there, and only by correcting it would we arrive at a definitive treatment of the disease."

Source: IDIBELL-Bellvitge Biomedical Research Institute, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 16, 2020
Cancer
APR 16, 2020
This drug hopes to prevent cancer relapse
A report published in Nature Communications highlights findings from a study showing that the experimental drug, Qu ...
APR 21, 2020
Health & Medicine
APR 21, 2020
How to Read COVID-19 News (Without Going Crazy)
  It can feel like COVID-19 news is consuming the country, and taking all the toilet paper and N95-masks with it. N ...
APR 27, 2020
Drug Discovery & Development
APR 27, 2020
Making Cardiac Medicine From Foxglove Plants
Foxglove plants are known to be shaped like bells and have long decorated many gardens. They belong to a genus of plants ...
MAY 03, 2020
Drug Discovery & Development
MAY 03, 2020
Hydroxychloroquine: The Controversial Use
COVID-19 was declared a public health threat on January 30th and since then it took the world by a storm with more than ...
MAY 18, 2020
Cancer
MAY 18, 2020
How do Ohnologs affect Cancer?
Genetics can be complicated to say the least. Sometimes it can be as simple as a single mutation in one gene that causes ...
MAY 30, 2020
Cancer
MAY 30, 2020
Linking an Aggressive Tumor Factor to the Innate Immune Response
Epithelial Ovarian Cancer (EOC) is a cancer of the fallopian tubes with a low five-year survival rate with a tendency to ...
Loading Comments...